Mallinckrodt
Mallinckrodt Q2 FY24: net loss $43.3M; diluted EPS −$2.20
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001567892-24-000030
- Document
- 10-Q
- Exhibit 4.3
- Warrants or notes
- Exhibit 10.1
- Material contract
- Exhibit 10.2
- Material contract
- Exhibit 10.3
- Material contract
- Exhibit 10.4
- Material contract
- Exhibit 10.5
- Material contract
- Exhibit 10.6
- Material contract
- Exhibit 10.7
- Material contract
Key figures from this report
These are the numbers Mallinckrodt reported for Q2 FY24, the quarter ended Jun 28, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Net income−$43.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$2.20No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$291.1MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
- Cash from operations$31.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.
- America Great Health AAGH
- Nika Pharmaceuticals NIKA
- Regenerex Pharma RGPX
- CNBX Pharmaceuticals CNBX public float $252K, Aug 31, 2025
- NovAccess Global XSNX public float $338K, Mar 31, 2025, over 18 months old